Eosinophilic esophagitis sales will expand through 2036, with corticosteroids at 47% of the drug class segment in 2026. The market was valued at USD 282.1 million in 2025 and is expected to be worth USD 4262.97 million by 2036, creating an incremental opportunity of USD 3901.88 million worldwide.